Revalesio

Revalesio aims to develop a new class of therapeutics for acute and chronic neurological disorders. Its team includes people from diverse backgrounds.

Revalesio is a clinical-stage pharmaceutical company developing treatments for stroke and age-related neurological disorders with inadequate therapeutic options. Its therapies target mitochondrial dysfunction and bioenergetic failure.

Revalesio is a clinical-stage pharmaceutical company focused on bioenergetic failure. Its research targets mitochondria and metabolic imbalances that drive post-stroke damage to the brain and cerebral vascular system.

Revalesio's privacy policy, last updated in June 2021, describes information, including personal data, that may be collected from website visitors.

Revalesio presents post-hoc analysis of its Phase 2 RESCUE trial at the SVIN 2025 conference, focusing on RNS60. The data suggest the experimental treatment may reduce hospital stay durations for patients with neurological disorders. The company specializes in developing therapies for acute and chronic neurological conditions.

Nov 2025PR NewswireNews article

Revalesio’s experimental drug **RNS60** secures FDA Fast Track designation as a neuroprotective treatment for **ischemic stroke**. The designation accelerates development for this cytoprotective agent, which targets brain cell preservation during stroke events. Clinical trials are underway to evaluate its safety and efficacy in reducing neurological damage.

Aug 2025neurologylive.comNews article

Revalesio presents details of its **Phase 3 trial design** and **post-hoc analysis of the Phase 2 RESCUE trial** for **RNS60**, a treatment candidate for **acute ischemic stroke**, at the **SNIS 22nd Annual Meeting**. The company’s two abstracts on RNS60 are accepted for oral presentation, highlighting progress in late-stage development for neurological disorders. Presentations occur during the conference in Nashville, TN, from July 14–18, 2025.

Jul 2025BioSpaceNews article

Revalesio presents its Phase 3 trial design for **RNS60**, a treatment for acute ischemic stroke, at the **Society of NeuroInterventional Surgery (SNIS) 22nd Annual Meeting**. The company also shares a post hoc analysis of its Phase 2 **RESCUE trial**, evaluating the drug’s potential in stroke therapy. The updates focus on advancing RNS60 toward late-stage validation in neurological disorders.

Jul 2025PR NewswireNews article